{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:25:06Z","timestamp":1787135106296,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01090-0","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:04:52Z","timestamp":1783785892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and multicohort external validation of a preoperative [18F]PSMA-1007 PET-derived deep learning score and multimodal model for predicting biochemical recurrence-free survival after radical prostatectomy"],"prefix":"10.1186","volume":"26","author":[{"given":"Tiancheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"2","key":"1090_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27(2):192\u2013201.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"1090_CR2","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2214\/AJR.19.21905","volume":"214","author":"P Bhargava","year":"2020","unstructured":"Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed? AJR Am J Roentgenol. 2020;214(6):1248\u201358.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"1090_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86(2):148\u201363.","journal-title":"Eur Urol"},{"issue":"2","key":"1090_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86(2):164\u201382.","journal-title":"Eur Urol"},{"issue":"9","key":"1090_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119\u201334.","journal-title":"Ann Oncol"},{"issue":"11","key":"1090_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969\u201374.","journal-title":"JAMA"},{"issue":"4","key":"1090_CR7","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.juro.2007.11.061","volume":"179","author":"SA Boorjian","year":"2008","unstructured":"Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D\u2019amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008;179(4):1354\u201360. discussion 60\u2009\u2013\u20091.","journal-title":"J Urol"},{"issue":"2","key":"1090_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1148\/radiol.2021202771","volume":"299","author":"C Lawhn-Heath","year":"2021","unstructured":"Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, et al. Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology. 2021;299(2):248\u201360.","journal-title":"Radiology"},{"key":"1090_CR9","doi-asserted-by":"crossref","unstructured":"Sweere V, Bruins Slot A, Hermsen R, Heetman JG, Wever L, Lavalaye J, et al. Prognostic value of PSMA PET\/CT-based local staging in predicting biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2026;53:921\u201330.","DOI":"10.1007\/s00259-025-07455-0"},{"issue":"6","key":"1090_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.eururo.2023.06.022","volume":"84","author":"L Djaileb","year":"2023","unstructured":"Djaileb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, et al. Presurgical (68)Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. Eur Urol. 2023;84(6):588\u201396.","journal-title":"Eur Urol"},{"issue":"9","key":"1090_CR11","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1007\/s00259-022-05756-2","volume":"49","author":"MJ Roberts","year":"2022","unstructured":"Roberts MJ, Morton A, Papa N, Franklin A, Raveenthiran S, Yaxley WJ, et al. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2022;49(9):3289\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1090_CR12","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1090_CR13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00259-016-3447-9","volume":"43","author":"FL Giesel","year":"2016","unstructured":"Giesel FL, Cardinale J, Schafer M, Neels O, Benesova M, Mier W, et al. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43(10):1929\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1090_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.117.196329","volume":"59","author":"FL Giesel","year":"2018","unstructured":"Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, et al. Biochemical Recurrence of Prostate Cancer: Initial Results with [(18)F]PSMA-1007 PET\/CT. J Nucl Med. 2018;59(4):632\u20135.","journal-title":"J Nucl Med"},{"key":"1090_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.media.2017.07.005","volume":"42","author":"G Litjens","year":"2017","unstructured":"Litjens G, Kooi T, Bejnordi BE, Setio AAA, Ciompi F, Ghafoorian M, et al. A survey on deep learning in medical image analysis. Med Image Anal. 2017;42:60\u201388.","journal-title":"Med Image Anal"},{"key":"1090_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-bioeng-071516-044442","volume":"19","author":"D Shen","year":"2017","unstructured":"Shen D, Wu G, Suk HI. Deep Learning in Medical Image Analysis. Annu Rev Biomed Eng. 2017;19:221\u201348.","journal-title":"Annu Rev Biomed Eng"},{"issue":"13","key":"1090_CR17","doi-asserted-by":"publisher","first-page":"E2970","DOI":"10.1073\/pnas.1717139115","volume":"115","author":"P Mobadersany","year":"2018","unstructured":"Mobadersany P, Yousefi S, Amgad M, Gutman DA, Barnholtz-Sloan JS, Velazquez Vega JE, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. Proc Natl Acad Sci U S A. 2018;115(13):E2970\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1090_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40644-025-00938-1","volume":"25","author":"K Min","year":"2025","unstructured":"Min K, Lin Q, Qiu D. Precision medicine in prostate cancer: individualized treatment through radiomics, genomics, and biomarkers. Cancer Imaging. 2025;25(1):116.","journal-title":"Cancer Imaging"},{"issue":"1","key":"1090_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12880-025-01914-8","volume":"25","author":"E Jafari","year":"2025","unstructured":"Jafari E, Zarei A, Dadgar H, Keshavarz A, Abdollahi H, Samimi R, et al. Efficacy of PSMA PET\/CT radiomics analysis for risk stratification in newly diagnosed prostate cancer: a multicenter study. BMC Med Imaging. 2025;25(1):375.","journal-title":"BMC Med Imaging"},{"issue":"1","key":"1090_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11701-025-02786-4","volume":"19","author":"E Rajih","year":"2025","unstructured":"Rajih E, Borhan WM, Elhassan YH, Elhakim A. Machine learning-based prediction of post-operative outcomes in robotic-assisted radical prostatectomy: a multi-variable analysis of 758 cases. J Robot Surg. 2025;19(1):631.","journal-title":"J Robot Surg"},{"key":"1090_CR21","doi-asserted-by":"crossref","unstructured":"Mastroleo F, Villa R, Zaffaroni M, Vincini MG, Franzese C, Nicosia L, et al. Penalized-survival nomogram predicts 5-year metastasis-free survival after salvage radiotherapy for postprostatectomy patients: a multicenter study. Clin Genitourin Cancer. 2025;23(6):102415.","DOI":"10.1016\/j.clgc.2025.102415"},{"key":"1090_CR22","doi-asserted-by":"crossref","unstructured":"Sutera P, Van der Eecken K, Song Y, Shetty AC, Davicioni E, Proudfoot JA, et al. Genomic predictors of response to metastasis-directed therapy with or without androgen deprivation therapy. Eur Urol Oncol. 2026;9(2):227\u201331.","DOI":"10.1016\/j.euo.2025.07.007"},{"key":"1090_CR23","doi-asserted-by":"publisher","first-page":"1647384","DOI":"10.3389\/fimmu.2025.1647384","volume":"16","author":"Z Liu","year":"2025","unstructured":"Liu Z, Li Y, Wang J, Zeng Y, Wu Q, Zhu X, et al. Integrative single-cell and machine learning analysis predicts lactylation-driven therapy resistance in prostate cancer: a molecular docking and experiments-validated framework for treatment optimization. Front Immunol. 2025;16:1647384.","journal-title":"Front Immunol"},{"issue":"9","key":"1090_CR24","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1007\/s00259-024-06734-6","volume":"51","author":"T Li","year":"2024","unstructured":"Li T, Xu M, Yang S, Wang G, Liu Y, Liu K, et al. Development and validation of [18F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024;51(9):2806\u201318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1090_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2016;69(3):428\u201335.","journal-title":"Eur Urol"},{"issue":"5","key":"1090_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","volume":"61","author":"JI Epstein","year":"2012","unstructured":"Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61(5):1019\u201324.","journal-title":"Eur Urol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01090-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01090-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01090-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:36:33Z","timestamp":1787132193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01090-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01090-0","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of The First Affiliated Hospital, Zhejiang University School of Medicine (Approval No. IIT20230803A). The study was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective study design and the use of de-identified data. Clinical trial number: Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"110"}}